HOME >> BIOLOGY >> NEWS
Jane Lubchenco receives the 2005 AAAS Public Understanding of Science and Technology Award

AAAS, the world's largest general scientific society, today named Jane Lubchenco, Wayne and Gladys Valley Professor of Marine Biology and Distinguished Professor of Zoology at Oregon State University, to receive the prestigious Public Understanding of Science and Technology Award for her exemplary commitment to, and leadership of, public understanding of science initiatives in public policy and professional arenas.

Dr. Lubchenco's career and extracurricular activities demonstrate her commitment to communicating science and technology to such diverse audiences as civic groups, school children, and local, national and international leaders as well as religious leaders and captains of business and industry. She also has used her substantial skills to create and lead at least two different organizations that train other scientists to become active public communicators.

"Dr. Lubchenco has shown us that public communication is both necessary and appropriate for scientific leadership," said Alan I Leshner, chief executive officer of AAAS and executive publisher of the journal, Science. "Through her example, many scientists and engineers are moving beyond efforts just to educate or help the public understand scientific concepts, and instead are promoting an open dialogue on issues affecting all our lives."

A marine ecologist by training, Dr. Lubchenco is engaged in a wide range of scientific, teaching and public service activities to help address serious environmental problems by making the best possible information and expertise more accessible to government leaders and improving the public's understanding of ecology. She launched the Aldo Leopold Leadership Program in 1998 under the Ecological Society of America to help outstanding environmental scientists become more effective communicators to the public and to policy-makers, as well as the media and private sector. In 1999, she co-founded the Communication Partnership for Science and the Sea, a
'"/>


15-Feb-2006


Page: 1 2

Related biology news :

1. Carnegie Mellons Peter Adams receives EPA research grant
2. Philadelphia ecologist receives top Mongolia honor
3. VIB scientist receives major research grant
4. Maynard Olson receives $500,000 Gruber Genetics Prize
5. University of Cincinnati receives $1.7M to research molecular treatment of brain injury
6. Wright State scientist receives grant to help clean up polluted American harbors
7. UCR biologist receives $1.75 million grant to study plant-threatening bacteria
8. Michael R. Zalutsky receives SNMs 2007 Paul C. Aebersold Award
9. Nobel laureate James Watson receives personal genome in ceremony at Baylor College of Medicine
10. MBL scientist Julie Huber receives 2007 LOral USA Fellowship for Women in Science
11. Weill Cornell pharmacologist receives prestigious NIH MERIT Award

Post Your Comments:
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: